InvestorsHub Logo
Followers 827
Posts 119564
Boards Moderated 15
Alias Born 09/05/2002

Re: DewDiligence post# 796

Wednesday, 01/24/2024 9:39:09 AM

Wednesday, January 24, 2024 9:39:09 AM

Post# of 803
ABT 4Q23 Results by Business Segment


%Corp YoY Growth
Segment Sales (const currency)

Medical devices* 43% +17%
Nutrition 20% +13%
Diagnostics 25% -22%†
Pharmaceuticals‡ 12% +9%

61% of overall corporate sales were ex-US.

*Includes diabetes care.
‡Branded generics and biosimilars in emerging markets.

†4Q23 COVID-diagnostics sales were $288M (11% of total 4Q23 diagnostic sales) vs $1.07B in 3Q22; excluding COVID diagnostics, 4Q23 diagnostics sales were +2% YoY.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ABT News